| Title |
Molecular genetic and immunotherapeutic targets in metastatic melanoma
|
|---|---|
| Published in |
Virchows Archiv, March 2017
|
| DOI | 10.1007/s00428-017-2113-3 |
| Pubmed ID | |
| Authors |
C. Melis, A. Rogiers, O. Bechter, Joost J. van den Oord |
| Abstract |
In recent years, melanoma treatment has radically changed with the emergence of targeted therapies and immunotherapies. Both have led to improved survival for patients with advanced or unresectable melanoma. Targeted therapies with BRAF inhibitors in the lead use the presence of activating driver mutations to inhibit tumour growth. Forty to 60% of melanomas harbour BRAF mutations, which makes them susceptible to treatment with BRAF and/or MEK inhibitors. In parallel, the development of immunotherapeutic agents has also expanded. These agents stimulate the endogenous immune system of the patient to eradicate cancer cells. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death 1 (PD-1) resulted in durable responses in a subset of patients. An important issue with immunotherapy lies in the identification of patients who will benefit from treatment. In this review, we will discuss these recent developments in melanoma therapy and highlight the role of the pathologist in both types of treatment. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 23% |
| Student > Bachelor | 7 | 18% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 2 | 5% |
| Student > Doctoral Student | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 14 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 18% |
| Biochemistry, Genetics and Molecular Biology | 5 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 13% |
| Agricultural and Biological Sciences | 4 | 10% |
| Immunology and Microbiology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 17 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2017.
All research outputs
#17,884,576
of 22,962,258 outputs
Outputs from Virchows Archiv
#1,443
of 1,964 outputs
Outputs of similar age
#220,502
of 308,778 outputs
Outputs of similar age from Virchows Archiv
#20
of 39 outputs
Altmetric has tracked 22,962,258 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,964 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,778 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.